Pharmaceutical Fine Chemicals Ltd · 66-66 · BAHAMAS
For Pharmaceutical Fine Chemicals Ltd, import alert is 66-66; country is BAHAMAS; import alert name is "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"; product is Doxazosin Mesylate; product code is 62 O - S 27 Doxazosin Mesylate (Anti-Hypertensive - Part II), Active Pharm Ingred/Chems for Further Manuf; date published is 09/30/2009; address is Po Box F-2430 , Freeport, City of Freeport BAHAMAS, verified against its source on 2026-09-30.
- Firm
- Pharmaceutical Fine Chemicals Ltd verified
- Import alert
- 66-66
- Import alert name
- "APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122"
- Country
- BAHAMAS verified
- Address
- Po Box F-2430 , Freeport, City of Freeport BAHAMAS verified
- Date published
- 09/30/2009 verified
- Product code
- 62 O - S 27 Doxazosin Mesylate (Anti-Hypertensive - Part II), Active Pharm Ingred/Chems for Further Manuf verified
- Product
- Doxazosin Mesylate verified
- FDA notes
- 11/2/2000 verified
What the source says
Pharmaceutical Fine Chemicals Ltd Date Published : 09/30/2009 Po Box F-2430 , Freeport, City of Freeport BAHAMAS
— accessdata.fda.gov, retrieved 2026-09-15
Where each value comes from
The values above are stated away from the sentence quoted with the answer, so the passage that states them is shown here too.
Product code, Product and FDA notes
62 O - S 27 Doxazosin Mesylate (Anti-Hypertensive - Part II), Active Pharm Ingred/Chems for Further Manuf Date Published: 04/02/2019 Desc: Doxazosin Mesylate Notes: 11/2/2000
— all from accessdata.fda.gov, retrieved 2026-09-15
Source
- accessdata.fda.govhttps://www.accessdata.fda.gov/cms_ia/importalert_202.html